The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
BJD, 2023.
Oras A. Alabas, Kayleigh J. Mason, Zenas Z.N. Yiu, Richard B. Warren, Nick Dand, Jonathan N.W.N. Barker, Catherine H. Smith, Christopher E.M. Grifï¬ths, the BADBIR and BSTOP study group.
Read publication: BJD
Related
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study...
Characteristics of "super responders" and "super nonresponders" to first biologic monotherapy for ps...
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic ...
0 Comments